乳腺癌分子分类临床病理745例分析

    Molecular classification in breast cancer: a clinicopathological analysis of 745 cases

    • 摘要: 目的:探讨乳腺癌分子分类及其各种亚型的临床病理学特征。方法:回顾性分析既往研究中曾用免疫组织化学S-P法检测浸润性乳腺癌中癌细胞表达雌激素受体、孕激素受体和表皮生长因子受体蛋白表达的病例,按照分子分类的标准重新分类,观察各种亚型的临床病理学特点,并与WHO组织学分类相比较。结果:将符合标准的745例浸润性乳腺癌分为5种分子亚型:管腔A型235例,管腔B型95例,表皮生长因子受体过表达型141例,基底细胞样型/三阴性型142例,其余132例未确定分类。描述各亚型临床病理特点。结论:乳腺癌的分子分类与WHO组织学分类间有一定对应关系。免疫组织化学标记有助于分子分类,分子分类亚型对于治疗和预后具有更直接的关系,值得进一步推广应用和标准化。

       

      Abstract: Objective: To explore the molecular classification in breast cancer and the clinicopathological features of variant subtypes.Methods: The expression of ER,PR and HER2 (C-erbB-2) in the cases of breast cancer detected immunohistochemically (S-P method) were studied retrospectively.The cases were reclassified according to the standard of molecular classification,and the clinicopathological features were observed and compared with the WHO histological classification.Results: The invasive breast carcinomas 745 cases were divided into 5 subtypes according to the molecular classification.Among these cases,luminal A subtype accounted for 235 cases,luminal B subtype 95 cases,HER2 overexpressing subtype 141 cases and basal-like subtype (BLBC)/triple negative breast cancer 142 cases,respectively.The remainder was not classified.The clinicopathological features were described.Conclusions: The moleculai and histological classifications of breast cancer are partly responsive.Immuohistochemical technique is helpful standardization to the molecular classification,which is more directly related to the therapy and prognosis and so worthy of wide employment and further standardization.

       

    /

    返回文章
    返回